We are committed to providing our customers with the objective, functional information they need to help with the early detection of vision disorders and enhanced patient management. See what your colleagues are saying about our efforts.
Diopsys provides an in-office ERG platform that allows clinicians to establish a functional baseline in diabetic retinopathy, and then follow disease in a way that we can’t otherwise.
I can tell you there’s never been a more exciting time in ophthalmology, and especially in the field of retina. We’re now able to treat the most serious diseases and also prevent, and even predict, their causes. And one of the things that’s been missing, and the reason I use my Diopsys system, is because we need objective metrics to measure our treatments and guide our function.
In my 40 some years in this business, this is the first time that we’ve been able to get real, objective evidence of how the retina’s doing in a host of conditions.
Before we had our Diopsys® NOVA™ ERG and VEP Vision Testing System, I would be hard-pressed to send somebody for an ERG. But with this office-based device, not only can we do these tests more efficiently, now we can explore and handle diseases that we never thought of doing electrophysiology for.
Now I have a reliable, objective test of retinal function that I can perform pre-operatively to give me an idea of what’s going on behind the cataract. Flicker ERG has helped me ensure that these patients are accurately prepared for the outcome of their surgery.
Pattern ERG is a technology that allows us to have earlier diagnosis or confirmation of glaucoma than anything else that we currently use.
The VEP results correlated significantly with the severity of visual field damage, but the results were obtained objectively, which helps give eye care specialists more confidence in the findings.
In my world, I’m testing patients with cataracts, glaucoma, macular degeneration, and retinal pathology. It’s not your typical assumption of what electrophysiology would be, and I think that’s the beauty of the Diopsys® NOVA™ system. It’s allowing doctors like me to be able to take this technology and actually elucidate a lot of these problems in our practice.
The holy grail for glaucoma or all forms of progressive optic neuropathy is to be able to answer, ‘is the problem in the retina or is the problem in the visual pathway behind the eye?’ Now there’s a way of doing this that we didn’t have before (with the Diopsys® NOVA™). Not only is it helping us understand today’s patient, but it’s going to help us develop new therapies that will save a lot of morbidity and save a lot of sight in our own lifetime.
We are using the Diopsys® NOVA™ ERG and VEP Vision Testing System in a variety of patients. We’re using it in patients with low tension glaucoma where it’s difficult to ascertain what’s happening because they have a “normal” pressure. They may have a totally normal visual field, but they have a very abnormal optic disc, so in those patients, this electrophysiologic testing is of great help.
A study in Documenta Ophthalmologica showed the Diopsys® NOVA™ is a reliable and reproducible device; making this technology extremely useful for detection of pathologies affecting the entire visual pathway.
Glaucoma is one of our biggest practice growth drivers the last couple of years. The best way to treat glaucoma is to catch it as early as possible in order to alter the disease curve. The Diopsys® NOVA™ Vision Testing System fits into our diagnostic glaucoma suite so elegantly and clinically.
I find Diopsys flicker ERG useful to help me decide how often I need to see a diabetic patient. If I have someone with mild NPDR whose phase responses are good, I’m likely to follow them maybe once a year, but if I have another diabetic with the same visibly evident mild NPDR, whose Diopsys testing suggests to me that the global cone function is down, I’m likely to follow them more often.
The Diopsys® NOVA™ ERG and VEP Vision Testing System has played an important role in helping us determine how well a patient is responding to therapy. When we lower eye pressure enough or treat these patients appropriately, we can see improvement in function. This technology is very sensitive. When we measure structure, say with OCT, we may not see the improvement.
A game-changer in glaucoma diagnostics (Diopsys®NOVA™) is technology that utilizes ERG and VEP in-office to detect ganglion cell suffering prior to damage that is permanent and irreversible.
